Ahmedabad-based Torrent Pharmaceuticals is seeing significant early success in India's semaglutide market, quickly capturing a substantial share after the drug's patent expired. The company's strategic move to introduce generic oral and injectable semaglutide formulations, combined with the integration of JB Pharma, is strengthening its presence in chronic therapies and driving robust financial performance.
Semaglutide Launch Drives Market Dominance
Torrent Pharmaceuticals launched its generic semaglutide brands, Sembolic (oral) and Semalix (injectable), in India in March 2026, immediately following the patent expiry on March 20. This made Torrent the first Indian company to offer a generic oral semaglutide alongside injectable versions. As of April 2026, PharmaTrac data indicates that Torrent's generic semaglutide portfolio has already secured a remarkable 38% market share across both formats.
The injectable version was introduced at a competitive starting price of Rs 3,999 per month, positioning Torrent strongly in the burgeoning diabetes and obesity treatment segment. This swift market entry has been a key factor in the company's recent growth.
Strategic Acquisition of JB Pharma Bolsters Portfolio
Beyond the semaglutide launch, Torrent's acquisition of a controlling stake in JB Pharma, with financials consolidated from January 21, 2026, has significantly expanded its therapeutic footprint. This transaction has broadened Torrent's scale in critical areas such as cardiovascular, diabetes, and gastroenterology, while also extending its reach to more doctors in the domestic market.
Strong Financial Performance Reported
The company reported impressive financial results for the March quarter. Torrent's India business revenues surged by 43% year-on-year, reaching Rs 2,215 crore. Excluding the contribution from JB Pharma, the base India business still grew by 15%, outperforming the Indian Pharmaceutical Market's overall growth of 10% (according to AIOCD PharmaTrac data).
Chronic and sub-chronic therapies account for nearly 75% of Torrent's India revenues, making semaglutide a natural and impactful addition to its long-duration treatment portfolio. This focus on chronic care aligns with the company's long-term growth strategy.
International Growth and Future Pipeline
Torrent's international operations also showed strong momentum. Revenues from Brazil increased by 30% to Rs 455 crore during the quarter. The company has a promising pipeline of 58 products currently under review with Brazil's regulatory authority, ANVISA, indicating potential for future launches. In the US market, revenues rose by 31% to Rs 396 crore, supported by recent product introductions.
Overall, Torrent Pharmaceuticals reported consolidated revenues of Rs 4,197 crore for the March quarter, marking a 42% increase year-on-year, largely attributed to the successful integration of JB Pharma and the strong performance of its core businesses.